289 related articles for article (PubMed ID: 24861629)
21. Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies.
Salarinia R; Sahebkar A; Peyvandi M; Mirzaei HR; Jaafari MR; Riahi MM; Ebrahimnejad H; Nahand JS; Hadjati J; Asrami MO; Fadaei S; Salehi R; Mirzaei H
Curr Cancer Drug Targets; 2016; 16(9):773-788. PubMed ID: 26638884
[TBL] [Abstract][Full Text] [Related]
22. Impact of DNA and RNA Methylation on Radiobiology and Cancer Progression.
Chi HC; Tsai CY; Tsai MM; Lin KH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29439529
[TBL] [Abstract][Full Text] [Related]
23. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application.
Hu C; Liu X; Zeng Y; Liu J; Wu F
Clin Epigenetics; 2021 Aug; 13(1):166. PubMed ID: 34452630
[TBL] [Abstract][Full Text] [Related]
24. Dual targeting of epigenetic therapy in cancer.
Hellebrekers DM; Griffioen AW; van Engeland M
Biochim Biophys Acta; 2007 Jan; 1775(1):76-91. PubMed ID: 16930846
[TBL] [Abstract][Full Text] [Related]
25. Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics.
Li Y; Li Z; Zhu WG
Curr Med Chem; 2019; 26(8):1328-1350. PubMed ID: 28933282
[TBL] [Abstract][Full Text] [Related]
26. What is the potential of epigenetics in drug development?
Lundstrom K
Future Med Chem; 2015; 7(3):239-42. PubMed ID: 25826357
[No Abstract] [Full Text] [Related]
27. Epigenetics in cancer therapy and nanomedicine.
Roberti A; Valdes AF; Torrecillas R; Fraga MF; Fernandez AF
Clin Epigenetics; 2019 May; 11(1):81. PubMed ID: 31097014
[TBL] [Abstract][Full Text] [Related]
28. Chromatin-modifying agents in anti-cancer therapy.
Seidel C; Florean C; Schnekenburger M; Dicato M; Diederich M
Biochimie; 2012 Nov; 94(11):2264-79. PubMed ID: 22627380
[TBL] [Abstract][Full Text] [Related]
29. Human DNA (cytosine-5)-methyltransferases: a functional and structural perspective for epigenetic cancer therapy.
Rondelet G; Wouters J
Biochimie; 2017 Aug; 139():137-147. PubMed ID: 28600135
[TBL] [Abstract][Full Text] [Related]
30. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic mechanisms of breast cancer: an update of the current knowledge.
Karsli-Ceppioglu S; Dagdemir A; Judes G; Ngollo M; Penault-Llorca F; Pajon A; Bignon YJ; Bernard-Gallon D
Epigenomics; 2014; 6(6):651-64. PubMed ID: 25531258
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy.
Lu Y; Chan YT; Tan HY; Li S; Wang N; Feng Y
Mol Cancer; 2020 Apr; 19(1):79. PubMed ID: 32340605
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic therapies reach main street.
Bates SE
Clin Cancer Res; 2009 Jun; 15(12):3917. PubMed ID: 19528089
[No Abstract] [Full Text] [Related]
34. Epigenetic regulation and cancer (review).
Chen QW; Zhu XY; Li YY; Meng ZQ
Oncol Rep; 2014 Feb; 31(2):523-32. PubMed ID: 24337819
[TBL] [Abstract][Full Text] [Related]
35. Epigenome-based personalized medicine in human cancer.
Yan W; Herman JG; Guo M
Epigenomics; 2016 Jan; 8(1):119-33. PubMed ID: 26344672
[TBL] [Abstract][Full Text] [Related]
36. Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
Mani E; Medina LA; Isaac-Olivé K; Dueñas-González A
Eur J Gynaecol Oncol; 2014; 35(2):140-2. PubMed ID: 24772915
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic modifications as therapeutic targets.
Kelly TK; De Carvalho DD; Jones PA
Nat Biotechnol; 2010 Oct; 28(10):1069-78. PubMed ID: 20944599
[TBL] [Abstract][Full Text] [Related]
38. Novel approaches on epigenetics.
Papait R; Monti E; Bonapace IM
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
[TBL] [Abstract][Full Text] [Related]
39. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
